CD33: Myeloid cell surface antigen CD33
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state.
- Drugs that act on it: 6
- Approved: 1
- In phases 1 to 3: 5
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CD33, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
- Antibody-drug conjugate
- Other
Modalities
Drugs on this target by ChEMBL molecule type.
- Antibody233%
- Antibody-drug conjugate117%
- Other350%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Myeloid cell surface antigen CD33 binding agent; the rest name their own mechanism.| Gemtuzumab ozogamicin | Approved | Pfizer | Antibody-drug conjugate | Binding agent | — | 25 | WithdrawnBoxed warning |
| Gemtuzumab | Phase 3 | — | Antibody | Binding agent | — | 26 | — |
| Lintuzumab | Phase 3 | Pfizer | Antibody | Other | Myeloid cell surface antigen CD33 other | 1 | — |
| M195 | Phase 2 | — | Other | Other | Myeloid cell surface antigen CD33 other | 0 | — |
| Oncolysin m | Phase 2 | — | Other | Binding agent | — | 0 | — |
| AVE-9633 | Phase 1 | Sanofi | Other | Binding agent | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Alzheimer disease
- 0.61
- Dementia
- 0.47
- Smoking initiation
- 0.42
- Myeloid leukemia
- 0.40
- Neoplasm
- 0.40
- Acute myeloid leukemia by FAB classification
- 0.39
- Dengue disease
- 0.37
- Parkinson disease
- 0.37
- Neurodegenerative disease
- 0.35
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1842, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20138, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets